Abstract
Interactions between Campylobacter jejuni and host immune cells have been studied using various single-cell line models, such as macrophages and intestinal epithelial cells; however, these single-cell approaches do not fully capture the complexity of the host response. Investigating the interactions between these cell types offers a more comprehensive model for understanding Campylobacter–host dynamics. Therefore, this study aimed to investigate these interactions, specifically between intestinal epithelial cells and macrophages, using an in vitro model of C. jejuni infection. We examined whether soluble factors secreted from C. jejuni-infected HT-29 cells (human colorectal adenocarcinoma cells that express characteristics of mature intestinal cells) at 10 and 50 multiplicities of infection (MOI) influence RAW 264.7 macrophage activity, including nitric oxide (NO) production, migration, phagocytosis, bacterial killing, and the expression of cytokines (IL-6, IL-1β, TNF-α) and the chemokine CCL2. C. jejuni infection of HT-29 cells at 10 MOI induced significant IFN-γ production, a key macrophage activator. The treatment of macrophages with supernatants from HT-29 cells infected with C. jejuni significantly increased NO production, enhanced migration and phagocytic activity, and increased IL-6, TNF-α and CCL2 gene expression. However, no significant killing of phagocytosed C. jejuni was observed. On the other hand, supernatants from HT-29 cells infected with 50 MOI of C. jejuni suppressed NO production and macrophage phagocytosis, which may explain individual variations in the immune system’s ability to contain infection, potentially influenced by the infectious dose. These findings support the notion that Campylobacter can evade macrophage killing even under activated conditions. Further studies are needed to elucidate the molecular mechanisms by which Campylobacter survives within activated macrophages.
1. Introduction
Campylobacter a Gram-negative, motile bacterium, is a leading bacterial cause of gastroenteritis in humans worldwide [1]. It is primarily transmitted through the consumption of contaminated animal products containing a low infectious dose of approximately 500 colony-forming units, causing an estimated 1.5 million cases of campylobacteriosis annually in the US, with associated healthcare costs ranging from $2 to $11 billion [1,2,3,4]. Campylobacteriosis in healthy individuals is typically a self-limiting disease; however, Campylobacter infections in immunocompromised and elderly individuals can lead to severe clinical manifestations, such as reactive arthritis, inflammatory bowel disease, and Guillain-Barré syndrome, necessitating antimicrobial treatment [5]. To date, there is a limited understanding of host immune surveillance in response to this pathogen and its ability to cause disease, which has hindered the development of innovative strategies for its prevention and control in humans.
Upon entering the intestinal tract, Campylobacter expresses several virulence factors, including motility-associated genes (FlaA, FlaB), adhesion genes (CadF, FlpA), and invasion genes (CiaB, iamA), which facilitate motility, adhesion to and invasion of intestinal epithelial cells (IECs) [6]. Following adhesion to IECs, bacteria either engage their PAMPs—such as lipooligosaccharide, flagellin, and lipoproteins—with transmembrane pattern recognition receptors (PRRs), particularly Toll-like receptors (TLRs), or are internalized by IECs, where they release outer membrane vesicles (OMVs) [7]. These OMVs, together with bacterial PAMPs, engage cytosolic PRRs, including NOD-like receptors (NLRs) [7,8]. Both pathways trigger intracellular signaling cascades that promote the secretion of cytokines and chemokines, such as interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-α), thereby initiating inflammation and recruiting additional immune cells [7]. In addition, Campylobacter has been reported to induce IFN-γ secretion from IECs, which contributes to macrophage activation, leading to the production of nitric oxide (NO) and reactive nitrogen species (RNS), both of which are known to possess potent bactericidal activity [7,9].
During infection, Campylobacter secretes cytolethal distending toxin [10], which also triggers inflammatory cytokine production, drives intestinal pathology and contributes to the epithelial barrier disruption [11,12,13]. It then uses its corkscrew-like motility, mediated by polar flagella, to traverse the damaged epithelium and reach the lamina propria, where other innate immune cells reside.
While neutrophils contribute to the clearance of bacterial pathogens, macrophages are believed to play a particularly critical role in Campylobacter infection because of their ability to efficiently phagocytose whole bacterial cells that cross the intestinal epithelial barrier and coordinate adaptive immunity [7,14]. Previous experimental studies by our group and others indicate that in vitro-cultured macrophages can phagocytose Campylobacter; however, whether Campylobacter can survive within macrophages or is rapidly killed after internalization remains controversial [6,15,16,17]. For instance, while Banfi and colleagues suggested that macrophages can eliminate Campylobacter through both intracellular and extracellular killing mechanisms [15], other studies have reported that Campylobacter can survive and even replicate within human macrophages after phagocytosis [15,17]. This discrepancy may be due to strain-specific or host-specific differences or differences in macrophage activation status. Nonetheless, these studies typically assess the phagocytic activity of cultured macrophages without activation by immunomodulators secreted by other host cells in vivo.
In addition to investigating Campylobacter–macrophage interactions, studies using IECs have delineated several virulence factors associated with Campylobacter motility, adhesion, and invasion, as well as the innate immune responses initiated upon bacterial entry into the intestinal tract. While investigations focused on a single innate immune cell type—such as IECs or macrophages—have provided important insights into Campylobacter virulence and host responses, they do not fully capture the complexity of cellular interactions during infection.
Therefore, this study was conducted to evaluate the in vitro interactions between IECs and macrophages during Campylobacter infection, providing a more comprehensive model of early Campylobacter–host interactions. Specifically, we examined how soluble factors secreted by Campylobacter-infected IECs influence macrophage NO production, migration, phagocytosis and killing of Campylobacter, as well as their cytokine and chemokine secretion patterns.
2. Materials and Methods
2.1. Preparation of Campylobacter Culture
A pure culture of C. jejuni strain 81-176 was prepared as described previously [18]. Briefly, Brain Heart Infusion (BHI) agar, containing Preston selective Campylobacter supplement (Oxoid, Basingstoke, Hampshire, UK), was streaked with a frozen loopful of C. jejuni. Following streaking, the plates were incubated in microaerophilic conditions (10% CO2, 5% O2, and 85% N2) at 37 °C for 48 h. A 5 mL freshly prepared BHI broth was then inoculated with a few numbers of colonies, followed by re-incubation under the same microaerobic conditions for 48 h at 37 °C. Afterwards, 0.5 mL of this culture was transferred to 50 mL of BHI broth, incubated under the same conditions for 48 h. Subsequently, the bacterial suspension underwent centrifugation at 3500× g for 10 min. The pellet was then resuspended in phosphate-buffered saline (PBS, pH 7.4). The optical density of the suspension was measured at 600 nm using a spectrophotometer (VWR, Radnor, PA, USA), and the corresponding colony-forming units (CFU)/mL were calculated using the growth formula.
2.2. Stimulation of HT-29 Cells with Campylobacter
HT-29 cells (human colorectal adenocarcinoma cells), provided by Dr. Jeremy Tzeng, Department of Biological Sciences at Clemson University, were seeded in six replicates in a 24-well plate (Corning Inc., Corning, NY, USA) at a density of 1 × 106 cells/well in 1 mL of DMEM containing 4.5 g/L glucose, L-glutamine, and sodium pyruvate, supplemented with 10% fetal bovine serum (FBS), 200 U/mL penicillin, and 80 µg/mL streptomycin and incubated at 37 °C in a humidified atmosphere with 5% CO2. The cells were allowed to adhere for 4 h, during which more than 90% became attached. Subsequently, the cells were infected with C. jejuni at a multiplicity of infection (MOI) of 10 or 50 in 1 mL of fresh DMEM per well or maintained in DMEM without C. jejuni as a negative control. C. jejuni was added to wells containing DMEM alone, without cells, at an MOI of 10 or 50. Cells were then incubated for 2, 6, 12, and 24 h at 37 °C in a humidified 5% CO2 incubator. However, prolonged incubation for 24 h resulted in excessive bacterial overgrowth, leading to complete destruction of the HT-29 cell monolayers. The culture media also turned yellow, indicating a drop in pH due to bacterial metabolism, which further compromised cell viability. Based on these observations, incubation times were limited to a maximum of 12 h. Following incubation, the plates were centrifuged at 300 × g for 3 min, and the supernatants were subsequently collected and filtered through a 0.45 μm syringe filter to remove bacterial cells. The supernatants from Campylobacter cultured in DMEM without cells were tested for their ability to induce NO production in RAW cells, in order to determine whether the induction was due to soluble factors secreted by Campylobacter-infected HT-29 cells or by C. jejuni itself.
2.3. Evaluation of the Cytotoxic Effects of Campylobacter on HT-29 Cells
The Colorimetric CyQUANT™ LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific, Greenville County, SC, USA) was used to evaluate the effects of two concentrations of C. jejuni on the viability of HT-29 cells. Briefly, cells were seeded as described above and incubated with live Campylobacter at an MOI of 10 or 50. For spontaneous LDH release, triplicate wells were incubated with 10 µL of sterile medium. An additional five replicate wells of non-infected cells served as the negative control. After 2, 6, and 12 h of incubation at 37 °C, 10 µL of 10× lysis buffer was added to each well to determine maximum LDH release. LDH supplied in the kit was used as a positive control, in accordance with the manufacturer’s instructions. The plate was then incubated for 45 min at 37 °C, and the supernatants were collected. Cellular cytotoxicity was quantified in five independent HT-29 culture replicates, as per the manufacturer’s instructions. Optical density (OD) was measured at 490 nm, and the percentage of cytotoxicity was calculated using the following formula:
% Cytotoxicity = ((Compound-treated LDH activity − Spontaneous LDH activity)/(Maximum LDH activity − Spontaneous LDH activity)) × 100
- -
- Compound-treated LDH: LDH activity in the HT-29 supernatant-treated wells;
- -
- Spontaneous LDH: LDH activity in the distilled water-treated wells (baseline release);
- -
- Maximum LDH: LDH activity after complete lysis of cells (total release).
2.4. Evaluation of IFN-γ Production in Campylobacter-Infected HT-29 Cells
IFN-γ production by HT-29 cells in response to infection with 10 or 50 MOI of C. jejuni was measured in the supernatant of six replicates of infected and non-infected cells using the BD OptEIA™ Human IFN-γ ELISA Kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s instructions.
2.5. Evaluation of NO Production in Macrophages Following Treatment with Supernatant from Campylobacter-Infected HT-29 Cells
NO production in RAW264.7 cells (monocyte/macrophage-like cells), provided by Dr. Alexis Stamatikos, Department of Food, Nutrition, and Packaging Sciences at Clemson University, was quantified following treatment with the supernatant of C. jejuni-infected HT-29 cells, using the Griess assay (Promega, Madison, WI, USA) following the manufacturer’s instructions. Briefly, RAW264.7 cells were seeded in five replicates at a density of 4 × 105 cells/well in 500 μL of supplemented DMEM in 48-well plates and incubated for 3 h at 37 °C in a humidified 5% CO2 incubator to allow adherence, which typically exceeds 90%. After 3 h, the DMEM was replaced with supernatants from Campylobacter-infected HT-29 cells (containing host cell factors such as cytokines and chemokines and possible C. jejuni components such as secreted proteins, toxins, and OMVs) or cell-free Campylobacter supernatants (containing C. jejuni components), and cells were incubated for 2, 6, or 12 h under the same conditions. The supernatants were then collected for measuring NO.
To quantify NO, 50 μL of modified Griess reagent was added to 50 μL of the collected cell-free culture supernatants (from treated RAW cells or cell-free Campylobacter supernatants in DMEM) in a 96-well flat-bottom plate, yielding a final volume of 100 μL per well. After a 15-min incubation at room temperature, absorbance was measured at 540 nm using the PerkinElmer multimode plate reader. The concentration of nitrite (NO2−) released was calculated by interpolation from a standard curve of sodium nitrite (NaNO2).
2.6. Evaluation of Macrophage Migration Following Treatment with Supernatant from Campylobacter-Infected HT-29 Cells
The Transwell migration assay was performed as previously described [19] with slight modifications. Briefly, RAW264.7 cells were seeded in six replicates at a density of 1 × 105 cells/100 μL DMEM containing 0.1% BSA, 4.5 g/L glucose, L-glutamine, and sodium pyruvate, supplemented with 10% fetal bovine serum (FBS), 200 U/mL penicillin, and 80 μg/mL streptomycin. Cells were plated on the membrane of a Transwell insert (Costar, Arlington, VA, USA) and incubated for 10 min at 37 °C in a humidified incubator with 5% CO2. To the lower chamber, 600 μL of supernatant derived from C. jejuni-infected HT29 cells (10 or 50 MOI) or control DMEM was added. After incubation for 24 h at 37 °C with 5% CO2, the media and non-migrated cells on the upper surface of the membrane were gently removed with a cotton swab. For fixation, the membrane was immersed in 800 μL of 70% ethanol for 10 min, followed by staining with 0.2% crystal violet for an additional 10 min. Excess dye was washed off with distilled water, and membranes were imaged using an inverted microscope. Migrated cells were quantified in four images captured from different non-overlapping fields using ImageJ software (version 1.54p).
2.7. Evaluation of Macrophage Phagocytic Activity Following Treatment with Supernatant from Campylobacter-Infected HT-29 Cells
The phagocytic activity of RAW264.7 cells was quantitatively assessed using a phagocytosis assay kit (Latex Beads Rabbit IgG-FITC; Cayman Chemical, Ann Arbor, MI, USA) following treatment with the supernatant from C. jejuni-infected HT-29 cells, as previously described [6]. Briefly, RAW264.7 cells were seeded in 96-well flat-bottom plates (4 × 105 cells/well) in supplemented DMEM medium, with six replicates per treatment, and incubated for 3 h at 37 °C in a 5% CO2 incubator. Cells were then treated with supernatants derived from HT-29 cells infected with an MOI of 10 or 50, or with supernatants from non-infected control cells, in the presence of the Latex Beads Rabbit IgG-FITC complex. Following a 6-h incubation at 37 °C in a humidified 5% CO2 environment, the cells were centrifuged at 400× g for 10 min, and the supernatant was discarded. Fluorescence intensity was measured using a multimode plate reader (PerkinElmer, Shelton, CT, USA) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
2.8. Evaluation of Macrophage Bactericidal Activity Against Campylobacter Following Treatment with Supernatant from Campylobacter-Infected HT-29 Cells
The gentamycin protection assay was performed as previously described [20], with minor modifications. Briefly, RAW264.7 cells were seeded at a density of 1 × 106 cells/well in 1 mL of supplemented DMEM in 24-well plates and incubated for 3 h at 37 °C in a humidified 5% CO2 incubator to allow adherence. Two identical plates were prepared for two timepoints, T0 and T2, each containing three experimental groups with five replicates per group. Before treatment, the medium was aspirated, and cells were washed twice with PBS. Supernatants derived from Campylobacter-infected HT-29 cells were prewarmed to 37 °C and added to wells (1 mL/well), and cells were then infected with 10 MOI of C. jejuni. Plates were centrifuged at 286× g for 3 min to facilitate contact between C. jejuni and RAW264.7 cells, followed by incubation at 37 °C with 5% CO2. After 2 h, the medium was aspirated, and the cells were washed three times with PBS. Then, 1 mL DMEM containing 200 μg/mL gentamicin was added to each well and incubated for either 15 min (T0) or 2 h (T2). Following incubation, cells were washed three times with PBS to remove residual antibiotic, then lysed with 1 mL of filter-sterilized 1% saponin in distilled water per well for 10 min, followed by vigorous pipetting. Lysates from each well were serially diluted (10-fold, up to four dilutions) in PBS and plated on BHI agar supplemented with Preston Campylobacter Selective Supplement. Plates were incubated under microaerobic conditions (5% O2, 10% CO2, 85% N2) at 37 °C for 48 h. CFUs of C. jejuni were enumerated, and bacterial killing was calculated using the formula: Killing percentage = [(T0 − T2)/T0] × 100.
2.9. Evaluation of Gene Expressions of Cytokine and Chemokine in Macrophages Following Treatment with Supernatant from Campylobacter-Infected HT-29 Cells
2.9.1. RNA Isolation and cDNA Preparation from Macrophages
Total RNA was extracted from six replicate macrophage cultures treated with supernatants from C. jejuni–infected HT-29 cells (MOI 10 or 50) for 2, 6, or 12 h using the Direct-zol RNA Kit (Zymo Research, Irvine, CA, USA), according to the manufacturer’s instructions. RNA concentration and purity were assessed using a Nanodrop One spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). First-strand cDNA was synthesized from the isolated RNA using the Superscript® II First-Strand Synthesis Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) with oligo(dT) primers (Thermo Fisher Scientific, Waltham, MA, USA) as previously described [21]. The resulting cDNA was diluted 1:10 in nuclease-free water (Thermo Fisher Scientific, Waltham, MA, USA) and stored at −20 °C until further use.
2.9.2. Quantitative Real-Time PCR (qRT-PCR)
PCR amplification was carried out on a qTOWER3 real-time PCR system (Analytik Jena, Jena, Germany) using SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) as previously described [22]. Each 20 µL reaction contained 10 µL of 2× SYBR Green mix, 1 µL each of forward and reverse primers diluted 1:10 from stock solutions of 100 µM, 5 µL of the template sample, and 3 µL of nuclease-free water. Primer sequences are provided in Table 1. Cycling conditions consisted of an initial denaturation at 95 °C for 2–3 min, followed by 40 cycles of 95 °C for 10–15 s, annealing at 55 °C for 20–30 s, and extension at 72 °C for 15–30 s. A final extension step was performed at 72 °C for 2–5 min. The specificity of amplification was confirmed by melt-curve analysis, performed from 65 to 95 °C with increments of 0.3–0.5 °C and 5–10 s holds per step. Relative gene expression was analyzed using the 2−ΔΔCt method, with GAPDH serving as the reference control. Data were expressed as fold changes relative to the control group.
Table 1.
Primer sequences used for quantitative real-time qRT-PCR.
2.10. Statistical Analysis
Graphs were created using GraphPad Prism V5.0 (GraphPad Software, San Diego, CA, USA). Data from 5–6 biological replicates per assay were analyzed using one-way analysis of variance (ANOVA) to determine whether statistically significant differences existed among the treatment groups. When ANOVA indicated a significant effect, Tukey’s multiple comparison test was applied as a post hoc analysis to identify which specific groups differed from each other. Results were considered statistically significant if the p value ≤ 0.05. Data are graphically represented as the mean ± the standard error of the mean (SEM).
3. Results
3.1. Campylobacter-IECs Interactions
3.1.1. Cytotoxic Effect of Campylobacter on IECs
This assay was performed to assess whether C. jejuni at two different concentrations (10 and 50 MOI) exerts cytotoxic effects on HT-29 cells using a lactate dehydrogenase (LDH) release assay. The results showed no significant differences in cytotoxicity between infected and non-infected cells, with overall values not exceeding 5% in the infected groups (Figure 1). Based on these findings, these two concentrations were used for subsequent experiments.
Figure 1.
Cytotoxicity of HT-29 cells was measured by the colorimetric CyQUANT™ LDH cytotoxicity assay kit in five biological replicates of HT-29 cells following infection with Campylobacter jejuni at 10 or 50 MOI for 2, 6, and 12 h. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. No significant differences were observed between the infected and non-infected cells. This assay was repeated twice, yielding similar results with no significant differences.
3.1.2. Campylobacter Enhanced IFN-γ Production by IECs
The protein levels of IFN-γ were measured in the supernatant of C. jejuni-infected IECs as an indicator of immunomodulator secretion in response to Campylobacter and as a potent activator of macrophages. No significant differences were observed in IFN-γ levels at 2- and 6-h post-infection with 10 or 50 MOI of C. jejuni. However, a significant increase was detected at 12 h post-infection with both concentrations (Figure 2). Based on these observations, supernatants collected at the 12-h time point were selected for all subsequent macrophage assays, as this was the peak of IFN-γ production—a key macrophage activator—and it preceded the significant cell monolayer destruction and pH change observed at 24 h.
Figure 2.
Interferon (IFN)-γ levels in six biological replicates of HT-29 cells following infection with Campylobacter jejuni at 10 or 50 MOI for 2, 6, and 12 h. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. Results are presented as the mean ± SEM. Asterisks (*) indicate statistically significant increases in IFN-γ production (p < 0.05).
3.2. Campylobacter-Macrophage Interactions
3.2.1. Soluble Factors Secreted by Campylobacter-Infected IECs Stimulate NO Production in Macrophages
As an indicator of macrophage activity, NO levels were measured in the macrophages at 2-, 6-, and 12-h following treatment with supernatants from Campylobacter-infected IECs or from Campylobacter incubated in the same culture medium but without cells. While the Campylobacter cell-free supernatant from medium without HT-29 cells—likely containing secreted proteins, peptides, metabolic by-products, OMVs, and lipooligosaccharides (LOS)—significantly reduced NO production at both concentrations, a significant increase in NO production was observed in response to the supernatant from C. jejuni-infected HT-29 cells at 10 MOI at both 2- and 12-h post-treatment. Treatment with the supernatant from 50 MOI C. jejuni-infected IECs significantly reduced NO production at both 6- and 12-h post-treatment, whereas no significant change was observed at 2 h (Figure 3).
Figure 3.
Nitric oxide (NO) production by RAW 264.7 cells following treatment with the supernatant from five biological replicates of C. jejuni–infected HT-29 cells at 10 or 50 MOI or Campylobacter cell-free supernatant for 2-, 6-, and 12-h. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. Results are presented as the mean ± SEM. Asterisks (*) indicate statistically significant increases in NO production (p < 0.05), while pound symbols (#) indicate statistically significant decreases (p < 0.05).
3.2.2. Soluble Factors Secreted by Campylobacter-Infected IECs Promote Macrophage Migration Activity
Treatment of macrophages with supernatants from Campylobacter-infected HT-29 cells at both 10 and 50 MOI significantly increased macrophage migration in a dose-dependent manner compared to macrophages treated with supernatants from non-infected cells. However, no significant difference was observed in macrophage migration between the 10 and 50 MOI (Figure 4).
Figure 4.
RAW 264.7 cell migration across the transmembrane in response to supernatants from six biological replicates of HT-29 cultures infected with Campylobacter (MOI 10 or 50) for 24 h. Migrated cells were stained with crystal violet in the negative control/untreated group (a), cells treated with supernatants from HT-29 cells infected with Campylobacter at MOI 10 (b), and cells treated with supernatants from HT-29 cells infected at MOI 50 (c). Panel (d) shows quantification of migrated cells across multiple fields. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. Results are presented as the mean ± SEM. Asterisks (*) indicate statistically significant increases in cell migration (p < 0.05). The experiment was repeated twice, yielding a similar migration pattern.
3.2.3. Soluble Factors Secreted by Campylobacter-Infected IECs Enhance Macrophage Phagocytic Activity
Treatment of macrophages with supernatants from Campylobacter-infected IECs at 10 MOI significantly enhanced phagocytosis at 6 h post-treatment, with no significant changes observed at 2 or 12 h, while treatment with the supernatant from IECs infected at 50 MOI significantly reduced macrophage phagocytic activity at 12 h post-treatment, emphasizing the dose-dependent effect (Figure 5).
Figure 5.
Phagocytic activity of RAW 264.7 cells was measured using the Latex Beads Rabbit IgG-FITC kit following treatment with supernatants from six biological replicates of HT-29 cultures infected with Campylobacter jejuni at MOI 10 or 50 for 2-, 6-, and 12-h. Fluorescence intensity was measured using a plate reader with an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The higher fluorescence indicates higher phagocytosis. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. Results are presented as the mean ± SEM. Asterisks (*) indicate statistically significant increases in macrophage phagocytic activity (p < 0.05), while the pound symbol (#) indicates statistically significant decreases (p < 0.05).
3.2.4. Soluble Factors Secreted by Campylobacter-Infected IECs Did Not Influence the Macrophage Killing Activity
To assess whether macrophage activation enhances their ability to kill Campylobacter, a gentamicin protection assay was performed. Although the killing percentage was numerically higher in macrophages treated with supernatants from Campylobacter-infected HT-29 cells at both 10 and 50 MOI (25% and 8%, respectively), it was not significantly different from that observed in macrophages treated with supernatants from non-infected cells (Figure 6). Raw data are provided in Supplementary Table S1.
Figure 6.
Macrophage killing activity against Campylobacter jejuni was assessed using the gentamicin protection assay after treatment with supernatants from five biological replicates of HT-29 cultures infected with C. jejuni at MOI 10 or 50 for 12-h. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. Results are presented as the mean ± SEM. The experiment was repeated twice with consistent, non-significant results.
3.2.5. Soluble Factors Secreted by Campylobacter-Infected IECs Alter Cytokine and Chemokine Gene Expression in Macrophages
To gain insights into the immunomodulatory activity of soluble factors secreted by IECs in response to Campylobacter, we evaluated their effects on macrophage expression of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and the chemokine C-C motif chemokine ligand 2 (CCL2).
The treatment of macrophages with supernatants from Campylobacter-infected HT-29 cells at 10 or 50 MOI significantly increased IL-6 gene expression at 2 and 12 h, respectively, compared to macrophages treated with supernatants from non-infected cells. However, no significant differences were observed in the expression of this gene at 6 h post-treatment (Figure 7a).
Figure 7.
Gene expression of interleukin (IL)-6 (a), IL-1β (b), tumor necrosis factor alpha (TNF-α) (c) and C-C motif chemokine ligand 2 (CCL2) (d) was measured in six biological replicates of RAW 264.7 cells using quantitative real-time PCR (qRT-PCR) following treatment with supernatants from C. jejuni–infected HT-29 cells (MOI 10 or 50) for 2, 6, or 12 h. Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. Results are presented as mean ± SEM. Asterisks (*) indicate statistically significant increases in gene expression (p < 0.05), while pound symbols (#) indicate statistically significant decreases (p < 0.05).
With respect to IL-1β, a significant decrease in its expression was observed at 6 h post-treatment in the cells treated with supernatants from Campylobacter-infected HT-29 cells at 10 MOI, whereas a significant increase in expression was observed at 12 h following treatment with supernatants from Campylobacter-infected HT-29 cells at 50 MOI. No significant differences were observed in IL-1β expression at 2 h post-treatment (Figure 7b).
Similar patterns of significantly induced TNF-α (Figure 7c) and CCL2 (Figure 7d) gene expression were observed at 2-, 6-, and 12-h in the cells treated with supernatants from Campylobacter-infected HT-29 cells at 50 MOI. Treatment of macrophages with supernatants from Campylobacter-infected HT-29 cells at 10 MOI induced TNF-α expression only at 12 h post-treatment.
4. Discussion
Extensive in vitro research has examined interactions between Campylobacter and host immune cells, including IECs and macrophages [25,26,27,28]. Although these in vitro studies provide valuable insights into host–microbe interactions, including the identification of some mechanistic pathways and characterization of immune responses in these cells during Campylobacter infection, they do not fully recapitulate the in vivo gut environment. For example, most experiments have directly exposed in vitro-cultured macrophages to Campylobacter [25,26,27,28,29], overlooking potential pre- or co-activation by immunomodulatory molecules secreted by other immune cells, such as epithelial cells that first encounter the bacteria in the gut. Evaluating the interplay between Campylobacter and IECs, including the effects of their secreted molecules on macrophage activation, may offer deeper insight into immune activation than analyses focused on individual immune cell types. Therefore, this study was undertaken to evaluate the crosstalk between IECs and macrophages in an in vitro model, specifically investigating how IEC-secreted molecules in response to Campylobacter influence macrophage NO production, migration, phagocytosis, bacterial killing, and cytokine and chemokine secretion. IECs can release numerous immunomodulatory molecules in response to Campylobacter, including IFN-γ, TNF-α, and granulocyte-macrophage colony-stimulating factors (GM-CSF), all of which are known to stimulate macrophage activation [26,30]. IFN-γ was measured in particular due to its central role in promoting macrophage activation, M1 polarization, and antigen presentation [31,32].
To rule out cytotoxic effects of Campylobacter toxins on IECs, an LDH release assay was performed, revealing no significant differences between infected and non-infected cells. Exposure of IECs to Campylobacter significantly induced IFN-γ production, prompting an assessment of whether supernatants from these cells could enhance macrophage activity. Notably, supernatants from Campylobacter-infected IECs induced significant NO production in macrophages, whereas supernatants from Campylobacter incubated in medium without IECs suppressed NO production at both concentrations. This underscores the importance of IEC-macrophage crosstalk: while direct exposure of macrophages to Campylobacter-secreted proteins, such as proteins, toxins, and OMVs, suppresses NO, which could be a potential immune evasion strategy, the secreted molecules from IECs, such as cytokines, chemokines and other immunomodulatory molecules, counteract this effect. This could explain the eventual control of the infection in self-limiting cases [7,26,33]. Moreover, the suppression of NO production and macrophage phagocytosis in cells treated with supernatants from 50 MOI-infected IECs is likely due to the presence of higher levels of specific bacterial immunosuppressive factors in the cell-free medium, which may account for dose-dependent variations in the immune system’s ability to control infection [34]. However, since the in vitro model does not fully capture the complexities of the host response, further validation of these findings in a dose–response study in an animal infection model is warranted.
In the present study, macrophages migrated in a dose-dependent manner toward supernatants from Campylobacter-infected IECs, suggesting that infected IECs release chemoattractants that initiate macrophage recruitment before bacterial recognition and phagocytosis. This observation is consistent with earlier studies showing that Campylobacter-derived PAMPs stimulate human IECs to secrete IL-8 [11,13], which in turn recruits innate immune cells, including neutrophils and macrophages, to the site of infection [7,35,36].
Accumulating evidence highlights the role of macrophage phagocytosis in host defense against Campylobacter [35,37]. Yet, whether phagocytosed bacteria can resist killing and survive inside macrophages remains controversial, possibly because many in vitro assays lack co-activation of macrophages by secreted immunomodulatory products from other immune cells. In this study, co-activation of macrophages with secreted molecules from Campylobacter-infected IECs did not enhance bacterial killing despite increased NO production and phagocytosis. However, this finding should be interpreted with caution, as the lack of a statistically significant enhancement in bacterial killing may reflect limited assay sensitivity or a minimal biological effect. Another important consideration is the relatively short incubation periods in our study, where IECs were exposed to Campylobacter for a maximum of 12 h, which may not have been sufficient for the cells to fully release their modulatory molecules. Similarly, short-term exposure of HT-29 cells to supernatants from infected cells may not accurately capture the longer-term interactions that typically occur over a few days in an infected host. These observations are consistent with those of Anna Duda-Madej et al. (2025), who reported that a 24-h exposure to berberine was insufficient to confer a protective effect on colonocytes exposed to C. jejuni post-culture supernatant, with statistically significant differences observed only after 72 h of incubation [4]. Nonetheless, these findings provide insight into the pathogen’s ability to cause gastroenteritis in healthy individuals and support the notion that Campylobacter can persist intracellularly in macrophages for extended periods by subverting phagolysosomal killing [38].
The secretory molecules from C. jejuni-infected HT-29 cells at both 10 and 50 MOI induced macrophage expression of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, as well as the chemokine CCL2, in a dose- and time-dependent manner, all of which have been previously reported to contribute to the initiation of inflammation and the development of gastroenteritis [7]. Nevertheless, despite a robust pro-inflammatory gene expression profile (IL-6, TNF-α and CCL2) induced by epithelial signals, enhanced phagocytosis, and increased NO production, this activation was insufficient to enhance bacterial killing, highlighting the need to investigate additional molecular and cellular mechanisms underlying Campylobacter survival within activated macrophages.
Although this study did not investigate the underlying molecular mechanisms of IECs and macrophage activation, it provides valuable insight into the importance of IEC–macrophage interactions in controlling Campylobacter infection. It also emphasizes the significance of cellular communication in in vitro assays for understanding host–pathogen interactions, rather than studying individual cell types separately. Additionally, it suggests how different infectious doses of Campylobacter may influence the immune system’s capacity to respond to and clear infection. Future studies will include mass spectrometry-based profiling of the secreted molecules in the supernatants from Campylobacter-infected HT-29 cells, along with targeted cytokine-neutralization assays in macrophages, to identify the specific mediators responsible for macrophage activation. Additionally, incorporating protein-level analyses, such as ELISA, will enable the quantification of secreted cytokines and confirmation of the magnitude of the observed immune responses.
5. Conclusions
This study highlights the interplay between IECs and macrophages during Campylobacter infection, showing that macrophages can mount diverse immune responses to IEC-derived signals while still being unable to fully kill phagocytosed bacteria. This may explain why Campylobacter proliferates in the gut and causes inflammation despite an active immune response. Further research is needed to elucidate the mechanisms behind these interactions. For example, identifying the survival mechanisms of Campylobacter within macrophages, as well as the signaling molecules involved in macrophage activation and phagocytosis, could inform the development of future immune-based therapeutic interventions.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms13122808/s1, Figure S1: It shows the adherence of HT-29 cells after 4 hours of incubation; Table S1: Raw data of the gentamycin protection assay.
Author Contributions
K.A.: Supervision, Conceptualization, Project administration, Writing—original draft, Visualization, Validation, Methodology, Formal analysis, Data curation. S.S., M.N. and A.S.: Methodology, Data Analysis, Review & Editing. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Taha-Abdelaziz, K.; Singh, M.; Sharif, S.; Sharma, S.; Kulkarni, R.R.; Alizadeh, M.; Yitbarek, A.; Helmy, Y.A. Intervention Strategies to Control Campylobacter at Different Stages of the Food Chain. Microorganisms 2023, 11, 113. [Google Scholar] [CrossRef]
- Naguib, M.; Sharma, S.; Schneider, A.; Wehmueller, S.; Abdelaziz, K. Comparative Effectiveness of Various Multi-Antigen Vaccines in Controlling Campylobacter jejuni in Broiler Chickens. Vaccines 2024, 12, 908. [Google Scholar] [CrossRef]
- Naguib, M.; Sharma, S.; Schneider, A.; Bragg, A.J.; Abdelaziz, K. A multi-antigen Campylobacter vaccine enhances antibody responses in layer breeders and sustains elevated maternal antibody levels in their offspring. Poult. Sci. 2025, 104, 104898. [Google Scholar] [CrossRef]
- Duda-Madej, A.; Gagat, P.; Wiśniewski, J.; Viscardi, S.; Krzyżek, P. Impact of Isoquinoline Alkaloids on the Intestinal Barrier in a Colonic Model of Campylobacter jejuni Infection. Int. J. Mol. Sci. 2025, 26, 10634. [Google Scholar] [CrossRef]
- Sharma, S.; Kaur, S.; Naguib, M.; Bragg, A.; Schneider, A.; Kulkarni, R.R.; Nazmi, A.; Abdelaziz, K. Major Foodborne Bacterial Pathogens in Poultry: Implications for Human Health and the Poultry Industry and Probiotic Mitigation Strategies. Microorganisms 2025, 13, 2363. [Google Scholar] [CrossRef]
- Taha-Abdelaziz, K.; Astill, J.; Kulkarni, R.R.; Read, L.R.; Najarian, A.; Farber, J.M.; Sharif, S. In vitro assessment of immunomodulatory and anti-Campylobacter activities of probiotic lactobacilli. Sci. Rep. 2019, 9, 17903. [Google Scholar] [CrossRef] [PubMed]
- Hameed, A. Human Immunity Against Campylobacter Infection. Immune Netw. 2019, 19, e38. [Google Scholar] [CrossRef]
- Elmi, A.; Watson, E.; Sandu, P.; Gundogdu, O.; Mills, D.C.; Inglis, N.F.; Manson, E.; Imrie, L.; Bajaj-Elliott, M.; Wren, B.W.; et al. Campylobacter jejuni outer membrane vesicles play an important role in bacterial interactions with human intestinal epithelial cells. Infect. Immun. 2012, 80, 4089–4098. [Google Scholar] [CrossRef] [PubMed]
- Iovine, N.M.; Pursnani, S.; Voldman, A.; Wasserman, G.; Blaser, M.J.; Weinrauch, Y. Reactive nitrogen species contribute to innate host defense against Campylobacter jejuni. Infect. Immun. 2008, 76, 986–993. [Google Scholar] [CrossRef]
- Ketley, J.M. Pathogenesis of enteric infection by Campylobacter. Microbiology 1997, 143 Pt 1, 5–21. [Google Scholar] [CrossRef] [PubMed]
- Hickey, T.E.; McVeigh, A.L.; Scott, D.A.; Michielutti, R.E.; Bixby, A.; Carroll, S.A.; Bourgeois, A.L.; Guerry, P. Campylobacter jejuni cytolethal distending toxin mediates release of interleukin-8 from intestinal epithelial cells. Infect. Immun. 2000, 68, 6535–6541. [Google Scholar] [CrossRef] [PubMed]
- Wine, E.; Chan, V.L.; Sherman, P.M. Campylobacter jejuni mediated disruption of polarized epithelial monolayers is cell-type specific, time dependent, and correlates with bacterial invasion. Pediatr. Res. 2008, 64, 599–604. [Google Scholar] [CrossRef]
- Zheng, J.; Meng, J.; Zhao, S.; Singh, R.; Song, W. Campylobacter-induced interleukin-8 secretion in polarized human intestinal epithelial cells requires Campylobacter-secreted cytolethal distending toxin- and Toll-like receptor-mediated activation of NF-kappaB. Infect. Immun. 2008, 76, 4498–4508. [Google Scholar] [CrossRef]
- Heikema, A.P.; Koning, R.I.; Rico, S.D.D.S.; Rempel, H.; Jacobs, B.C.; Endtz, H.P.; van Wamel, W.J.B.; Samsom, J.N. Enhanced, sialoadhesin-dependent uptake of Guillain-Barre syndrome-associated Campylobacter jejuni strains by human macrophages. Infect. Immun. 2013, 81, 2095–2103. [Google Scholar] [CrossRef] [PubMed]
- Wassenaar, T.M.; Engelskirchen, M.; Park, S.; Lastovica, A. Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocytes/macrophages. Med. Microbiol. Immunol. 1997, 186, 139–144. [Google Scholar] [CrossRef] [PubMed]
- Banfi, E.; Cinco, M.; Zabucchi, G. Phagocytosis of Campylobacter jejuni and C. coli by peritoneal macrophages. J. Gen. Microbiol. 1986, 132, 2409–2412. [Google Scholar] [CrossRef]
- Day, W.A.; Sajecki, J.L.; Pitts, T.M.; Joens, L.A. Role of catalase in Campylobacter jejuni intracellular survival. Infect. Immun. 2000, 68, 6337–6345. [Google Scholar] [CrossRef]
- Taha-Abdelaziz, K.; Yitbarek, A.; Alkie, T.N.; Hodgins, D.C.; Read, L.R.; Weese, J.S.; Sharif, S. PLGA-encapsulated CpG ODN and Campylobacter jejuni lysate modulate cecal microbiota composition in broiler chickens experimentally challenged with C. jejuni. Sci. Rep. 2018, 8, 12076. [Google Scholar] [CrossRef]
- Justus, C.R.; Leffler, N.; Ruiz-Echevarria, M.; Yang, L.V. In vitro cell migration and invasion assays. J. Vis. Exp. 2014, 88, 51046. [Google Scholar] [CrossRef]
- Sharma, A.; Puhar, A. Gentamicin Protection Assay to Determine the Number of Intracellular Bacteria during Infection of Human TC7 Intestinal Epithelial Cells by Shigella flexneri. Bio. Protoc. 2019, 9, e3292. [Google Scholar] [CrossRef]
- Abdelaziz, K.; Nixon, T.; Joye, A.; Hassan, H.; Alizadeh, M.; Sharif, S.; Kulkarni, R.R. Modulation of functional activity of heat-stressed chicken macrophages by poultry-derived probiotic lactobacilli. Can. J. Anim. Sci. 2024, 104, 301–312. [Google Scholar] [CrossRef]
- Taha-Abdelaziz, K.; Alkie, T.N.; Hodgins, D.C.; Yitbarek, A.; Shojadoost, B.; Sharif, S. Gene expression profiling of chicken cecal tonsils and ileum following oral exposure to soluble and PLGA-encapsulated CpG ODN, and lysate of Campylobacter jejuni. Vet. Microbiol. 2017, 212, 67–74. [Google Scholar] [CrossRef] [PubMed]
- Huang, K.; Jo, H.; Echesabal-Chen, J.; Stamatikos, A. Combined LXR and RXR Agonist Therapy Increases ABCA1 Protein Expression and Enhances ApoAI-Mediated Cholesterol Efflux in Cultured Endothelial Cells. Metabolites 2021, 11, 640. [Google Scholar] [CrossRef] [PubMed]
- Fernando, L.; Echesabal-Chen, J.; Miller, M.; Powell, R.R.; Bruce, T.; Paul, A.; Poudyal, N.; Saliutama, J.; Parman, K.; Paul, K.S.; et al. Cholesterol Efflux Decreases TLR4-Target Gene Expression in Cultured Macrophages Exposed to T. brucei Ghosts. Microorganisms 2024, 12, 1730. [Google Scholar] [CrossRef]
- Aguilar, C.; Jiménez-Marín, Á.; Martins, R.P.; Garrido, J.J. Interaction between Campylobacter and intestinal epithelial cells leads to a different proinflammatory response in human and porcine host. Vet. Immunol. Immunopathol. 2014, 162, 14–23. [Google Scholar] [CrossRef]
- Callahan, S.M.; Dolislager, C.G.; Johnson, J.G. The Host Cellular Immune Response to Infection by Campylobacter spp. and Its Role in Disease. Infect. Immun. 2021, 89, e00116-21. [Google Scholar] [CrossRef]
- Kim, S.; Vela, A.; Clohisey, S.M.; Athanasiadou, S.; Kaiser, P.; Stevens, M.P.; Vervelde, L. Host-specific differences in the response of cultured macrophages to Campylobacter jejuni capsule and O-methyl phosphoramidate mutants. Vet. Res. 2018, 49, 3. [Google Scholar] [CrossRef]
- Chintoan-Uta, C. The host-pathogen interaction in Campylobacter jejuni infection of chickens: An understudied aspect that is crucial for effective control. Virulence 2017, 8, 241–243. [Google Scholar] [CrossRef]
- Li, P.; Cui, Y.; Guo, F.; Guo, J.; Cao, X.; Lin, J.; Ding, B.; Xu, F. Campylobacter jejuni infection induces dynamic expression of avian host defense peptides in vitro and in vivo. Vet. Microbiol. 2023, 277, 109631. [Google Scholar] [CrossRef]
- Shin, W.G.; Park, B.J.; Lee, S.J.; Kim, J.G. Infection of human intestinal epithelial cells by invasive bacteria activates NF-κB and increases ICAM-1 expression through NOD1. Korean J. Intern. Med. 2018, 33, 81–90. [Google Scholar] [CrossRef]
- Xie, C.; Liu, C.; Wu, B.; Lin, Y.; Ma, T.; Xiong, H.; Wang, Q.; Li, Z.; Ma, C.; Tu, Z. Effects of IRF1 and IFN-β interaction on the M1 polarization of macrophages and its antitumor function. Int. J. Mol. Med. 2016, 38, 148–160. [Google Scholar] [CrossRef] [PubMed]
- Park, D.; Lim, G.; Yoon, S.-J.; Yi, H.-S.; Choi, D.W. The role of immunomodulatory metabolites in shaping the inflammatory response of macrophages. BMB Rep. 2022, 55, 519–527. [Google Scholar] [CrossRef]
- Janssen, R.; Krogfelt, K.A.; Cawthraw, S.A.; van Pelt, W.; Wagenaar, J.A.; Owen, R.J. Host-Pathogen Interactions in Campylobacter Infections: The Host Perspective. Clin. Microbiol. Rev. 2008, 21, 505–518. [Google Scholar] [CrossRef]
- Tribble, D.R.; Baqar, S.; Scott, D.A.; Oplinger, M.L.; Trespalacios, F.; Rollins, D.; Walker, R.I.; Clements, J.D.; Walz, S.; Gibbs, P.; et al. Assessment of the Duration of Protection in Campylobacter jejuni Experimental Infection in Humans. Infect. Immun. 2010, 78, 1750–1759. [Google Scholar] [CrossRef]
- Jones, M.A.; To, S.; Maskell, D.J.; Bryant, C.E.; Barrow, P.A. Induction of Proinflammatory Responses in the Human Monocytic Cell Line THP-1 by Campylobacter jejuni. Infect. Immun. 2003, 71, 2626–2633. [Google Scholar] [CrossRef]
- Murphy, H.; Cogan, T.; Humphrey, T. Direction of neutrophil movements by Campylobacter-infected intestinal epithelium. Microbes Infect. 2011, 13, 42–48. [Google Scholar] [CrossRef]
- Bär, W. Role of murine macrophages and complement in experimental campylobacter infection. J. Med. Microbiol. 1988, 26, 55–59. [Google Scholar] [CrossRef] [PubMed]
- Hickey, T.E.; Majam, G.; Guerry, P. Intracellular Survival of Campylobacter jejuni in Human Monocytic Cells and Induction of Apoptotic Death by Cytholethal Distending Toxin. Infect. Immun. 2005, 73, 5194–5197. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).